CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

Zhang, Ni; Han, Jiaqi; Liu, Zijian; He, Jinlan; Tian, Kun; Chen, Nianyong

doi:10.3390/cancers15133386

Cited by 3 publications

(5 citation statements)

References 41 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Выживаемость без прогрессирования по материалам рандомизированных клинических исследований и исследований на данных реальной клинической практики [8-10, 15-21, 34] Table 3. Progression-free survival demonstrated by randomized controlled trials and studies based on routine clinical practice практики [8-10, 15-21, 34] [15,16,[22][23][24][31][32][33] Table 4. Comparison of overall survival [15,16,[22][23][24][31][32][33] Авторы исследования…”

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

“…Progression-free survival demonstrated by randomized controlled trials and studies based on routine clinical practice практики [8-10, 15-21, 34] [15,16,[22][23][24][31][32][33] Table 4. Comparison of overall survival [15,16,[22][23][24][31][32][33] Авторы исследования…”

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...mentioning

confidence: 99%

“…Рибоциклиб + ГТ (n = 54, в том числе 34 в комбинации с ИА) Абемациклиб + ГТ (n = 56, в том числе 29 в комбинации с ИА) Palbociclib + HT (n = 96, including 53 in combination with AI) Ribociclib + HT (n = 54, including 34 in combination with AI) Abemaciclib + HT (n = 56, including 29 in combination with AI) Палбоциклиб + ГТ (n = 79, в том числе 37 -в составе 1-й линии, 34 -в комбинации с ИА) Рибоциклиб + ГТ (n = 42, в том числе 33 -в составе 1-й линии, 31 -в комбинации с ИА) Абемациклиб + ГТ (n = 21, в том числе 9 -в составе 1-й линии, 9 -в комбинации с ИА) Palbociclib + HT (n = 79, including 37 as first-line therapy, 34 in combination with AI) Ribociclib + HT (n = 42 including 33 as first-line therapy, 31 in combination with AI) Abemaciclib + HT (n = 21, including 9 as first-line therapy, 9 in combination with AI) Палбоциклиб + ГТ (n = 33, в том числе 6 -в составе 1-й линии, 8 -в комбинации с ИА) Рибоциклиб + ГТ (n = 28, в том числе 19 -в составе 1-й линии, 25 -в комбинации с ИА) Palbociclib + HT (n = 33, including 6 as first-line therapy, 8 in combination with AI) Ribociclib + HT (n = 28, including 19 as first-line therapy, 25 in combination with AI)No Таблица 1. Общая характеристика отобранных исследований[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] …”

unclassified

“…General characteristics of the studies included[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] …”

mentioning

confidence: 99%

“…Результаты сравнительного анализа выживаемости без прогрессирования[15][16][17][22][23][24][25][26][27][28][29][30][31][32][33] …”

unclassified

See 4 more Smart Citations

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Avxentyev,

Andreyashkina,

Artamonova

et al. 2024

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment of locally advanced or metastatic breast cancer. However, direct comparisons of these treatment options in randomized studies have not been conducted.Aim of the work is to gather and analyze published data on the comparative effectiveness of CDK4/6 inhibitors in combination with aromatase inhibitors in postmenopausal patients with HR+/HER2– locally advanced or metastatic breast cancer. A systematic review of publications presenting results from original studies on the impact of CDK4/6 inhibitor therapy in combination with aromatase inhibitors on the survival of patients was performed. Nineteen studies with original data on progression-free survival and overall survival were identified. None of the studies found significant differences between different CDK4/6 inhibitors and aromatase inhibitors in terms of progression-free survival. A statistically significant superiority of ribociclib over palbociclib in terms of overall survival was observed in a single matching-adjusted indirect comparison, while seven other studies of various types (real-world data studies, matching-adjusted indirect comparisons, and meta-analyses) did not find significant differences between the investigated drugs in terms of overall survival.Currently, there is no compelling evidence of the superiority of one CDK4/6 inhibitor over others. The decision on the preference for a specific drug within the class can only be made after conducting direct randomized comparison trials, or accumulating sufficient real-world data on the use of palbociclib, ribociclib, and abemaciclib.

show abstract

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...mentioning

confidence: 99%

unclassified

“…General characteristics of the studies included[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] …”

mentioning

confidence: 99%

unclassified

See 3 more Smart Citations

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Avxentyev,

Andreyashkina,

Artamonova

et al. 2024

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

show abstract

Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer

Hong,

Chen,

Ouyang

et al. 2024

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

BackgroundDalpiciclib and abemaciclib, both CDK4/6 inhibitors, have been approved by the China National Medical Products Administration for the rst-line treatment of postmenopausal women with hormone receptorpositive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) advanced breast cancer (ABC). As the rst domestically developed CDK4/6 inhibitor in China, there has been no previous economic evaluation of dalpiciclib. This study aimed to assess the cost-effectiveness of dalpiciclib compared to abemaciclib when used in combination with letrozole for the rst-line treatment of HR+/HER2 − ABC from the perspective of healthcare payers in China. MethodsA Markov model with three health states was constructed to evaluate the health and economic outcomes of rst-line treatment with dalpiciclib plus letrozole and abemaciclib plus letrozole for HR+/HER2 − ABC.The e cacy data was obtained from the MONARCH3 and DAWNA-2 trials, while utility data was derived from published reports. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. Sensitivity analyses were performed to explore variations in the model results. ResultsCompared to abemaciclib plus letrozole, dalpiciclib plus letrozole resulted in 5.13 additional QALYs, with an ICER of $27,305/QALY. At a willingness-to-pay (WTP) threshold of the gross domestic product (GDP) per capita in China for 2022 ($38,223/QALY), the probability of dalpiciclib plus letrozole being costeffective was 75%. Sensitivity analysis results were consistent with those of the base-case analysis. ConclusionsFrom the perspective of Chinese healthcare payers, the combination of dalpiciclib and letrozole appears to be a more cost-effective strategy when compared to abemaciclib plus letrozole for the rst-line treatment of patients with HR+/HER2 − ABC in China.

show abstract

Cost-effectiveness comparison of dalpiciclib and abemaciclib Combined with an aromatase inhibitor as first-line treatment for HR+/ HER2− advanced breast cancer

Hong,

Chen,

Meng

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Dalpiciclib and abemaciclib, both CDK4/6 inhibitors, have been approved by the China National Medical Products Administration for the first-line treatment of postmenopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) advanced breast cancer (ABC). As the first domestically developed CDK4/6 inhibitor in China, there has been no previous economic evaluation of dalpiciclib. This study aimed to assess the cost-effectiveness of dalpiciclib compared to abemaciclib when used in combination with letrozole for the first-line treatment of HR+/HER2 − ABC from the perspective of healthcare payers in China. Methods A Markov model with three health states was constructed to evaluate the health and economic outcomes of first-line treatment with dalpiciclib plus letrozole and abemaciclib plus letrozole for HR+/HER2 − ABC. The efficacy data was obtained from the MONARCH3 and DAWNA-2 trials, while utility data was derived from published reports. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. Sensitivity analyses were performed to explore variations in the model results. Results Compared to abemaciclib plus letrozole, dalpiciclib plus letrozole resulted in 5.13 additional QALYs, with an ICER of $27,305/QALY. At a willingness-to-pay (WTP) threshold of the gross domestic product (GDP) per capita in China for 2022 ($38,223/QALY), the probability of dalpiciclib plus letrozole being cost-effective was 75%. Sensitivity analysis results were consistent with those of the base-case analysis. Conclusions From the perspective of Chinese healthcare payers, the combination of dalpiciclib and letrozole appears to be a more cost-effective strategy when compared to abemaciclib plus letrozole for the first-line treatment of patients with HR+/HER2 − ABC in China.

show abstract

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

Cited by 3 publications

References 41 publications

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review

Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer

Cost-effectiveness comparison of dalpiciclib and abemaciclib Combined with an aromatase inhibitor as first-line treatment for HR+/ HER2− advanced breast cancer

Contact Info

Product

Resources

About